Evidence map›Paper›PMID 37082696›Full record

ArticleAnnals of translational medicine2023

Jing Pan, Jun Xing, Haiyang Yu, Ziming Wang, Wei Wang, Yueyin Pan

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jing Pan *Department of Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
Jun Xing *Department of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Haiyang Yu *Department of Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
Ziming WangDepartment of Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
Wei WangDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Yueyin PanDepartment of Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
Anhui Provincial Hospital · CNUniversity of Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It has been shown that circular RNAs (circRNAs) are involved in the pathogenesis of non-small cell lung cancer (NSCLC). However, the molecular mechanisms of circRNAs in tumor malignant progression and tyrosine kinase inhibitors (TKI) resistance remain undefined. Hereby, we explored the mechanisms by which Methods: Transcriptome sequencing (RNA-seq) was carried out to obtain the Results: The sequencing results revealed that cirRBM33 was highly expressed in the cell line of osimertinib resistant H1975. Conclusions: CircRBM33 is upregulated in NSCLC and that knockdown of

Indexed as

circRBM33circular RNAs (circRNAs)drug-resistanceNon-small-cell lung cancer (NSCLC)osimertinib

Identifiers

PMID37082696
PMCPMC10113067
OpenAlexW4312982725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.